01 吉利德科学公司宣布，美国FDA已授予Trodelvy突破性疗法认定，用于治疗接受铂类化疗后疾病进展的广泛期小细胞肺癌 (ES-SCLC)成人患者。 04 目前，Trodelvy已在超过50个国家和地区获批，用于治疗经治转移性三阴性乳腺癌 ...

Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell ...

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Squamous Non-Small Cell Lung Cancer.

Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...

Background Endometrial cancer is the most common gynecologic malignancy in developed countries. Trop-2 is a glycoprotein involved in cellular signal transduction and is differentially ...

The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...

Trodelvy is the only approved Trop-2-directed antibody-drug conjugate that has demonstrated meaningful survival advantages in two different types of metastatic breast cancers, according to Gilead.1 ...

Our top content for the year highlight many challenges the field of non–small cell lung cancer (NSCLC) encountered, with data ...

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Ovarian Cancer.